Resistance is futile: Targeting the inhibitory FcγRIIB (CD32B) to maximize immunotherapy

DOI: 10.1080/2162402X.2015.1069939

Keywords: CD32B, FcgRIIB, immunotherapy, mAb resistance, monoclonal antibody, therapyrituximab

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text